|
A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) |
Necitumumab |
I4X-MC-JFCL |
NCT01769391 |
Squamous Non-Small Cell Lung Cancer |
Phase 2 |
|
|
Not available |
|
|
September 2017 |